Cargando…
Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements which are either unnecessary for effective gene delivery (e.g. bacterial origins of replic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082409/ https://www.ncbi.nlm.nih.gov/pubmed/24830436 http://dx.doi.org/10.1038/gt.2014.37 |
_version_ | 1782324253325000704 |
---|---|
author | Walters, Adam A. Kinnear, Ekaterina Shattock, Robin J. McDonald, Jacqueline U. Caproni, Lisa J. Porter, Neil Tregoning, John S. |
author_facet | Walters, Adam A. Kinnear, Ekaterina Shattock, Robin J. McDonald, Jacqueline U. Caproni, Lisa J. Porter, Neil Tregoning, John S. |
author_sort | Walters, Adam A. |
collection | PubMed |
description | The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements which are either unnecessary for effective gene delivery (e.g. bacterial origins of replication) or undesirable (e.g. antibiotic resistance genes). Removing these elements may improve the safety profile of DNA for the delivery of vaccines. Here we describe a novel, double-stranded, linear DNA construct produced by an enzymatic process that solely encodes an antigen expression cassette, comprising antigen, promoter, polyA tail and telomeric ends. We compared these constructs (called ‘Doggybones’ because of their shape) with conventional plasmid DNA. Using luciferase-expressing constructs, we demonstrated that expression levels were equivalent between Doggybones and plasmids both in vitro and in vivo. When mice were immunized with DNA constructs expressing the HIV envelope protein gp140, equivalent humoral and cellular responses were induced. Immunizations with either construct type expressing haemagluttinin were protective against H1N1 influenza challenge. This is the first example of an effective DNA vaccine which can be produced on a large scale by enzymatic processes. |
format | Online Article Text |
id | pubmed-4082409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
record_format | MEDLINE/PubMed |
spelling | pubmed-40824092015-01-01 Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines Walters, Adam A. Kinnear, Ekaterina Shattock, Robin J. McDonald, Jacqueline U. Caproni, Lisa J. Porter, Neil Tregoning, John S. Gene Ther Article The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements which are either unnecessary for effective gene delivery (e.g. bacterial origins of replication) or undesirable (e.g. antibiotic resistance genes). Removing these elements may improve the safety profile of DNA for the delivery of vaccines. Here we describe a novel, double-stranded, linear DNA construct produced by an enzymatic process that solely encodes an antigen expression cassette, comprising antigen, promoter, polyA tail and telomeric ends. We compared these constructs (called ‘Doggybones’ because of their shape) with conventional plasmid DNA. Using luciferase-expressing constructs, we demonstrated that expression levels were equivalent between Doggybones and plasmids both in vitro and in vivo. When mice were immunized with DNA constructs expressing the HIV envelope protein gp140, equivalent humoral and cellular responses were induced. Immunizations with either construct type expressing haemagluttinin were protective against H1N1 influenza challenge. This is the first example of an effective DNA vaccine which can be produced on a large scale by enzymatic processes. 2014-05-15 2014-07 /pmc/articles/PMC4082409/ /pubmed/24830436 http://dx.doi.org/10.1038/gt.2014.37 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Walters, Adam A. Kinnear, Ekaterina Shattock, Robin J. McDonald, Jacqueline U. Caproni, Lisa J. Porter, Neil Tregoning, John S. Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines |
title | Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines |
title_full | Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines |
title_fullStr | Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines |
title_full_unstemmed | Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines |
title_short | Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines |
title_sort | comparative analysis of enzymatically produced novel linear dna constructs with plasmids for use as dna vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082409/ https://www.ncbi.nlm.nih.gov/pubmed/24830436 http://dx.doi.org/10.1038/gt.2014.37 |
work_keys_str_mv | AT waltersadama comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines AT kinnearekaterina comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines AT shattockrobinj comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines AT mcdonaldjacquelineu comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines AT capronilisaj comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines AT porterneil comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines AT tregoningjohns comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines |